Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.

@article{Rubenfire2007TransitionFI,
  title={Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.},
  author={Melvyn Rubenfire and Vallerie V Mclaughlin and Roblee P. Allen and Greg Elliott and Myung Hoon Park and Michael Wade and Robert J. Schilz},
  journal={Chest},
  year={2007},
  volume={132 3},
  pages={
          757-63
        }
}
BACKGROUND We determined the relative efficacy of subcutaneous (SC) treprostinil in stable World Health Organization class II and III patients transitioned from IV epoprostenol. METHODS This was an 8-week, multicenter, randomized study in which patients were transitioned from IV epoprostenol to SC treprostinil or placebo over a period of up to 14 days and monitored carefully during and after the transition period for signs of deterioration. Patients with clinical deterioration were returned… CONTINUE READING
Highly Cited
This paper has 59 citations. REVIEW CITATIONS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation • 2017
View 2 Excerpts

Prostanoid therapies in the management of pulmonary arterial hypertension

Therapeutics and clinical risk management • 2015
View 1 Excerpt

60 Citations

0510'10'13'16'19
Citations per Year
Semantic Scholar estimates that this publication has 60 citations based on the available data.

See our FAQ for additional information.